Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Payables (2024 - 2025)

Historic Payables for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $2.3 million.

  • Xilio Therapeutics' Payables rose 13662.55% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 13662.55%. This contributed to the annual value of $2.6 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Payables stood at $2.3 million for Q3 2025, which was up 13662.55% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' Payables peaked at $4.1 million during Q2 2025, and registered a low of $746000.0 during Q1 2024.